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Persons with advanced cancer of the larynx or pyriform sinuses frequently 
undergo laryngeal amputation (laryngectomy) to remove the tumor.  Among the sequelae 
to this surgery are permanent diversion of the lower airway to a tracheostoma at the base 
of the neck with loss of the upper airway for respiration and olfaction, maintenance of 
oral swallowing (but altered by loss of the larynx and alteration of the upper esophageal 
sphincter), and loss of voice (Stemple, Glaze, & Klaben, 2000).   
There are three primary methods for voice restoration following total 
laryngectomy: esophageal speech, speech with an artificial vibratory source (a.k.a. 
electrolarynx), and tracheoesophageal (TE) speech, which requires a voice prosthesis 
(v.p.) (Stemple, Glaze, & Klaben, 2000).  The latter is the focus of the present study. 
Since the introduction of the first effective v.p. in 1980 (InHealth Technologies 
ENT Product Catalog, 2005), there has been a steady increase in the variety of designs of 
prostheses available for use.  This increase in variety raises questions about which design 
is “best” or what criteria should be employed in selecting v.p.s.   
The study is a chart review of a 29 patients with total laryngectomy and primary 
TEP who have been in recovery for at least one year (time frame, 2003-2004).  The goal 
is to identify changes in selected v.p.s and reasons for such changes in the first year post-
surgery.   
The primary trend was a reduction in v.p. length over the first year.  A second 
surprising trend was the relatively short useful life of the clinician-inserted v.p.s.  A third 
trend was the pervasive presence of candida colonization of voice prostheses (a condition 
which produces premature breakdown of the v.p. valve). 
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The larynx is important both in the protection of the airway and in phonation; 
however, do to its mucosal lining the larynx is susceptible to cancer.  The total 
laryngectomy has played a major role in the treatment of laryngeal cancer since 1873 
(Singer, 1983).  With laryngeal amputation the patient experiences a consequent loss or 
impairment of several important functions including respiration, deglutition, olfaction, 
phonation, and protection of the airway.  The surgeon removes the entire larynx, the 
inferior and superior muscular attachments, the hyoid bone, the extrinsic strap muscles, 
and possibly the upper two or three tracheal rings (Stemple, Glaze, & Klaben, 2000).  
The surgeon then anchors the trachea to the base of the neck creating a permanent 
opening called the tracheostoma (see Appendix A).  Because of this alteration, respiration 
no longer occurs through the upper airway, but through the tracheostoma. The surgeon 
also insures the integrity of the connection between the hypopharynx and the upper 
esophagus (Salmon & Mount, 1991).   
Both phonation and protection of the airway are disrupted when the larynx is 
removed.  The production of voice requires a vibratory body and a power source.  The 
vibratory body in a person with a fully intact vocal tract is the vocal folds which are 
housed in the larynx, and the power source is pulmonary or exhaled air from the lungs 
(Lombard, 1996).  Three options for voice restoration, esophageal speech, speech with an 
artificial larynx, and tracheoesophageal speech, are plausible solutions for the aphonia 
occurring after total laryngectomy (Stemple, Glaze, & Klaben, 2000).  However, all three 
methods have advantages and disadvantages, and the goal of the speech-language 
pathologist and otolaryngologist is to find the method best suited for the patient.  
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A major advantage of esophageal speech is the cost aspect.  This technique does 
not require expensive devices and prostheses.  However, its success rate of acquiring 
production is not very high because to produce esophageal speech, the patient must relax 
the esophageal sphincter volitionally (ORL – Oto Rhino Laryngology Web, 2002).  The 
resting state of a normal esophageal sphincter is tonic, and unless the sphincter has been 
damaged and weakened, due to a total laryngectomy for instance, esophageal speech may 
not be established.  Esophageal speech requires patience and practice as mastery of this 
form of speech can entail six months or more of therapy (WebWhispers.org, 2004).  For 
more information on esophageal speech see 
http://www.webwhispers.org/pages/library/esophageal.htm.  
Speech via an electrolarynx has its advantages and disadvantages as well.  The 
major advantage is that basic speech is learned quickly by most patients and does not 
interfere in learning other forms of alaryngeal speech.  On the other hand, disadvantages 
include the mechanical sound, a dependence on batteries, and the interference of the 
loudness of voice due to certain patient conditions.  Severe post-surgical scarring and 
radiation therapy with associated edema may interfere with transfer of sound into the 
resonant cavities of the vocal tract (ORL – Oto Rhino Laryngology Web, 2002). 
In order for the patient to obtain tracheoesophageal (TE) speech, the surgeon must 
create a fistula or puncture through the common walls of the trachea and esophagus either 
at the time of the total laryngectomy (primary puncture) or at some subsequent time 
(secondary puncture).  A voice prosthesis (v.p.) is inserted into the fistula, and the patient 
is able to speak by occluding the tracheostoma diverting pulmonary air from the lungs 
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through the v.p. into the upper esophagus where tissue vibrates to generate the sound 
source for speaking (InHealth Technologies, 2000-2005)(see Appendix B).  The v.p. is 
important not only to allow the air to flow from the trachea to the esophagus for voice 
production, but also to maintain the puncture and to prevent esophageal leakage into the 
trachea during swallowing (Blom, Information Data Sheet).  
The development of voice prostheses has improved immensely over the past 
seventy-four years from a simple goose quill to a silicone one-way slit valve (Singer, 
1983), and today, speech-language pathologists and otolaryngologists face a myriad of 
decisions when assisting the laryngectomee.  These decisions greatly affect the 
restoration of voice and can prevent isolation and depression for the post-laryngectomy 
patient.  Length, diameter, type of retention collar, method of insertion, and the patient’s 
ability to care for the prosthesis are among the factors the speech-language pathologist 
and otolaryngologist must consider in establishing TE speech for a patient.  The wrong 
decision results in an inability to communicate vocally.  The wrong prosthesis may also 
pose a dangerous risk of pneumonia (through chronic aspiration of fluids into the airway 
via the prosthesis) or of airway compromise associated with the prosthesis occupying 
space in the tracheostoma or actually dislodging and falling into the trachea 
(Laccourreye, et al., 1997).   
The idea that the upper esophageal sphincter, or pharyngoesophageal (PE) 
segment, could act as a sound source and the body of the esophagus as the air 
reservoir/power source for speech came about in 1922.  Since then, prostheses have 
evolved from simple goose quills to one-way valves made of medically high grade 
silicone.  In 1931, a post-laryngectomy patient pierced his own neck with a red hot ice 
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pick establishing a tracheal shunt, and he used a goose quill to maintain the puncture.  
Not until 1972 was the first commercially available v.p. developed, the Voice Bak.  It 
was expensive, awkward, and required regular mechanical maintenance (Singer, 1983).  
Eight years later Blom and Singer developed the original duckbill v.p. that has become 
the international standard for voice restoration over the past 25 years (InHealth 
Technologies ENT Product Catalog, 2005). 
One important distinction in the current generation of v.p.s is based on who is 
responsible for changing/replacing improperly functioning devices.  Clinician-inserted 
and patient-inserted devices serve the same purposes: to maintain the puncture, allow air 
to flow from the trachea to the esophagus for voice production, and to prevent esophageal 
leakage into the trachea during swallowing.  Both voice prostheses are cylindrical in 
shape and consist of a neck strap(s), a retention collar, and a slit, hinged, or balled valve.  
Both the neck strap(s) and retention collar help to keep the prosthesis in place.  However, 
the neck strap(s) is taped to the skin of the neck, and the retention collar grips the inside 
of the esophageal wall to prevent dislodgment.  The valve opens under positive pressure 
as air enters the esophagus, and it closes by elastic recoil (Stemple, Glaze, & Klaben, 
2000).  
The patient-inserted prosthesis can be removed, cleaned, and inserted by the 
patient.  However, the clinician-inserted v.p. is a more recent development that was 
created in hopes of solving self-care issues.  They contain larger tracheal and esophageal 
retention collars requiring a significantly greater effort to remove and replace the v.p. 
(Stemple, Glaze, & Klaben, 2000).  Although these v.p.s are purported to be more 
durable (lasting approximately 6 to 12 months), they are also more expensive.  As of 
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March 1, 2005, Inhealth’s patient-inserted duckbill v.p. was only 27 dollars, and the low 
pressure v.p. was only 43 dollars.  However, Inhealth’s clinician-inserted v.p. was 125 
dollars (Inhealth Technologies Patient Price List, 2005), and as of February 1, 2005, 
Atos’s clinician-inserted v.p. was 199 dollars (Atos Medical price list, 2005).  As of 
7/1/05, Medicare’s reimbursement for all voice prostheses, regardless of actual cost, was 
$88.09.  Aetna’s reimbursement was $78.69, United Health Care’s reimbursement was 
$136.00, and Medical Mutual’s reimbursement was $74.00 (Billing Information on 
Patient Records).   
  The duckbill, low-pressure, and ultra-low resistance v.p.s are three styles of 
patient-inserted devices (see Appendix C).  The duckbill v.p. is a 16 or 20 French (Fr.) 
silicone, one-way slit valve that is available in 9 standard lengths ranging from 6mm to 
28mm.  Patients may also order custom lengths if needed.  Out of the three patient-
inserted devices, the duckbill extends the farthest into the esophagus and would not be 
well suited for a patient whose esophageal lumen at the level of the TEF is too narrow to 
accommodate this device (Stemple, Glaze, & Klaben, 2000).   
The low pressure v.p. is also available in 9 standard lengths ranging from 6mm to 
28mm and in 2 diameters of 16 & 20 Fr. (Inhealth).  The low-pressure v.p. has a recessed 
valve and a low profile tip making it more difficult to insert the v.p. into the fistula.  This 
is why the Blom-Singer Gel Cap Insertion System was invented (Stemple, Glaze, & 
Klaben, 2000).    
Finally, the ultra-low resistance v.p. was available in 7 standard lengths ranging 
from 6mm to 22mm and in 2 diameters of 16 & 20 Fr. (Bivona), and this particular 
device contains a thinner retention collar and can be inserted and removed easier.  This is 
Ashley Lee: Factors Affecting Prosthesis Life in Tracheoesophageal Speech 
 
 
beneficial to patients with a sensitive TEF (Stemple, Glaze, & Klaben, 2000).  Bivona 
ceased manufacture of all v.p.s in late 2004.  
Atos’ Provox II and Inhealth’s Indwelling are two styles of clinician-inserted 
devices (See Appendix D).  The Provox II is a second-generation prosthesis that was 
introduced in 1997.  It contains several valuable features including low airflow resistance, 
easy maintenance, safe placement, detectable in x-ray, and high success rate.  It is a 21 
Fr. silicone one-way valve that is available in 6 standard lengths ranging from 4.5mm to 
15mm and may either be inserted retrograde using the Provox Guidewire or preferably 
anterograde using the single-use insertion tool (Atos Medical Catalog, 2005).   
The Indwelling v.p. is another clinician-inserted device that is also intended for 
patients who have self-care issues, such as an inability to perform the routine removal 
and insertion needed to clean the v.p.  It is a 20 Fr. silicone one-way valve available in 8 
standard lengths ranging from 6mm to 25mm.  Patients may also order custom lengths if 
needed (Inhealth Technologies ENT Product Catalog, 2005) (see Table 1 for a complete 
breakdown of v.p.s in the present study).  
The development of voice prostheses and tracheoesophageal speech has improved 
immensely over time.  Yet, there are still many potential complications.  Complications 
in this instance are defined as anything that prevents, delays, or interferes with voice 
restoration via tracheoesophageal speech.  These complications can be broken down into 
patient-related issues (Leder, et al., 1995) and prosthesis-related issues (Mäkitie, et al., 
2003).  Patient-related issues include self-care issues (Leder, et al., 1995) and related 
physical issues, such as pharyngoesophageal spasm, radiation-induced fibrosis, 
pneumonia, emphysema, recurrent cancer, and dysphagia.   
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Self-care issues involve removing, cleaning, and reinserting the v.p., and these 
issues are usually addressed when the patient is seen for the first visit with the speech-
language pathologist.  The removal of the prosthesis is accomplished by firmly grasping 
the v.p. and pulling forward.  The patient or clinician should then immediately insert a 
catheter or tracheoesophageal puncture dilator to prevent aspiration and stenosis.  Once 
the prosthesis is cleaned or to be replaced according to the instructions given by the 
manufacturer, the v.p. can be reinserted often with the Blom-Singer Gel Cap Insertion 
System (Stemple, Glaze, & Klaben, 2000).   
Another patient-related issue is the ability to readily occlude the stoma.  The 
tracheostoma valve is an optional device that may be used to eliminate this problem and 
is also beneficial for many patients who are required to use both hands while working.  
The tracheostoma valve consists of two components, a housing collar and a valve.  The 
housing collar is taped and glued to the tissue surrounding the stoma and may not be 
sufficient for patients with sunken stomas or uneven skin tissue surrounding the stoma.  
This patient may not have an adequate skin surface for collar adhesion.  When the patient 
develops sufficient pulmonary air pressure to produce speech, the valve will close, 
occluding the stoma and directing air into the v.p. (Stemple, Glaze, & Klaben, 2000).  
   The patient-related issue of pharyngoesophageal (PE) spasm is a complication 
in voice rehabilitation via tracheoesophageal speech that appears to be caused by 
reflexive contraction of the cricopharyngeal and constrictor muscles when the mid-
esophagus is distended with air (Quinn, 1996).  There are three options for recovery from 
PE spasm.  The patient can do nothing, because PE spasm is not a health hazard.  The 
patient can use a chemical (Botox injection) or surgery (PE myotomy) to weaken the 
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sphincter, or they can have the TEF resized to accommodate a larger diameter v.p.  The 
higher volume of air flow may assist the patient in managing the spasm (Stemple, Glaze, 
& Klaben, 2000). 
Another physical issue that affects the patient’s ability to produce voice is 
radiation induced fibrosis.  This is one of the various side effects associated with the use 
of radiation as an additional treatment before or after surgery.  Radiation is usually used 
to shrink a lesion prior to surgery or to destroy cancerous cells not detected post-surgery.  
In the latter case, patients obtain the best results if treatments begin 6 weeks following 
surgery and end within 100 days of surgery (Stemple, Glaze, & Klaben, 2000).  
Prosthesis-related issues break down into two subcategories, leakage around the 
v.p. and leakage through the v.p. (Mäkitie, et al., 2003).  Leakage around the device 
usually means that the lumen of the fistula or puncture has enlarged, and it no longer fits 
snugly around the shaft of the v.p.  This complication may have resulted spontaneously 
over time, or it may have resulted from wearing a v.p. that is too long.  When a v.p. is too 
long, the act of swallowing may push down on the esophageal end momentarily widening 
the diameter of the fistula.  This momentary widening may eventually enlarge the 
diameter of the fistula causing further complications in the future (Salmon & Mount, 
1991).   
On the other hand, leakage through the v.p. may either be the result of normal 
wear and tear or candida colonization.  Candida colonization is the deterioration of 
silicone caused by the candida organism (Salmon & Mount, 1991).  The risk of candida 
colonization may increase when the patient has had radiation treatment or frequent use of 
antibiotics (The Milton J. Dance, Jr. Head & Neck Rehabilitation Center, 1999). 
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Complications, such as an inability to readily occlude the stoma, PE spasm, 
radiation-induced fibrosis, and candida colonization may be inevitable; however, there 
are still many unanswered questions.  A few of these unanswered questions are:  
1) How does v.p. length change in the first year of recovery? 
2) How does v.p. diameter change in the first year of recovery? 
3) How many patients switch from a patient-inserted v.p. to a clinician-inserted v.p. 
and vice versa in the first year of recovery? 
4) Are there gender-related differences in speech rehabilitation in the first year of 
recovery?  
5) Do clinician-inserted v.p.s really last longer than patient-inserted v.p.s?   
6) How long do these v.p.s last before they wear out?   
7) Are there factors in patient speech rehabilitation more commonly found following 
radiation?   
Past studies have addressed some of these issues, but they have primarily focused 
on one or two types of v.p.s or only one manufacturer.  Laccourreye, et al. focused on the 
Provox clinician-inserted v.p. (Laccourreye, et al., 1997), and Leder and Sasaki only 
focused on Inhealth’s v.p.s (Leder & Sasaki, 1995).  However, the present study focuses 
on five different types of v.p.s from three different manufacturers and addresses these 
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      Materials and Methods 
Data Collection Procedure 
The present study is a retrospective charts review of all 48 patients with total 
laryngectomy and TEP treated at the Arthur G. James Cancer Hospital and Richard 
Solove Research Institute at the Ohio State University from January 2003 to the end of 
2004.  Information was gathered from the voice therapy and physician notes and 
compiled into an Excel spreadsheet.  The data consist of identification number, patient 
initials, date of birth, date of laryngectomy, related surgeries including flap 
reconstruction, pre or post-operation radiation treatment, date of voice therapy session, 
type and manufacturer of v.p., length of v.p., diameter of v.p., the patient’s ability to care 
for the v.p., reason for altering the v.p., competency in tracheoesophageal speech, related 
health conditions, related health treatment, insurance, physician, and speech-language 
pathologist.  The goal is to identify trends that may be beneficial in the clinical decision 
making process.  
Participants  
 The data collected consists of 36 men and 12 women with an age range from 32 
years, 5 months to 93 years, 4 months at the time of surgery.  Most patients (87%) were 
fitted with a v.p. between 17 and 60 days following total laryngectomy.  The earliest 
initial speech therapy session occurred 8 days after total laryngectomy, and the latest was 
at 235 days, with a mean period of 47.5 days and a median of 32 days.  In four cases the 
surgeon inserted the v.p. at the time of the laryngectomy. 
 




Essentially two types of voice prostheses, patient-inserted and clinician-inserted 
devices, were used.  Both are silicone one-way valves that serve the same purposes, to 
maintain the puncture, allow air to flow from the trachea to the esophagus for voice 
production, and to prevent esophageal leakage into the trachea during swallowing (Blom, 
Information Data Sheet).  However, the patient-inserted prosthesis can be removed, 
cleaned, and inserted by the patient, but the clinician-inserted v.p. stays in place until a 
problem persists.  Then, the patient must see a clinician to remove and replace the device 
(Stemple, Glaze, & Klaben, 2000). 
The duckbill, low-pressure, and ultra-low resistance are three styles of patient-
inserted devices.  The duckbill v.p. is a 16 or 20 Fr. silicone, one-way slit valve that is 
available in 9 standard lengths ranging from 6mm to 28mm.  Patients may also order 
custom lengths if needed.  Out of the three patient-inserted devices, the duckbill extends 
the farthest into the esophagus and would not be well suited for a patient whose 
esophageal lumen at the level of the TEF is too narrow to accommodate this device 
(Stemple, Glaze, & Klaben, 2000).   
The low pressure v.p. is also available in 9 standard lengths ranging from 6mm to 
28mm and in 2 diameters of 16 and 20 Fr. (Inhealth).  The low-pressure v.p. has a 
recessed valve and a low profile tip making it more difficult to insert the v.p. into the 
fistula.  This is why the Blom-Singer Gel Cap Insertion System was invented (Stemple, 
Glaze, & Klaben, 2000).    
Finally, the ultra-low resistance v.p. was available in 7 standard lengths ranging 
from 6mm to 22mm and in 2 diameters of 16 and 20 Fr. (Bivona), and this particular 
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device contains a thinner retention collar and can be inserted and removed easier.  This is 
beneficial to patients with a sensitive TEF (Stemple, Glaze, & Klaben, 2000).  Bivona 
ceased manufacture of all v.p.s in late 2004. 
Atos’ Provox II and Inhealth’s Indwelling are two styles of clinician-inserted 
devices.  The Provox II is a second-generation prosthesis that was introduced in 1997.  It 
contains several valuable features including low airflow resistance, easy maintenance, 
safe placement, detectable in x-ray, and high success rate.  It is a 21 Fr. silicone one-way 
valve that is available in 6 standard lengths ranging from 4.5mm to 15mm and may either 
be inserted retrograde using the Provox Guidewire or preferably anterograde using the 
single-use insertion tool (Atos Medical Catalog, 2005).   
The Indwelling v.p. is another clinician-inserted device that is also intended for 
patients who have self-care issues, such as an inability to perform the routine removal 
and insertion needed to clean the v.p.  It is a 20 Fr. silicone one-way valve available in 8 
standard lengths ranging from 6mm to 25mm.  Patients may also order custom lengths if 
needed (Inhealth Technologies ENT Product Catalog, 2005).     
      Results 
Participants    
The present study was a retrospective charts review of 48 patients with total 
laryngectomy and TEP who had completed one year of recovery.  Of these 48 patients, 
19 were lost to follow-up either because of a referral to another facility closer to the 
patient’s home (6), a TEP closure (10), or ceased service at the James Cancer Hospital 
(3).  Of the remaining 29 patients, 27 had completed at least 12 months of recovery, and 2 
had TEP closure just prior to 12 months (range 9-11 months).  This latter group was 
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retained for data analysis, as their experience basically reflected the first year of recovery.  
Of these 29 patients, there were 20 men and 9 women with an age range from 41 years, 
11 months to 81 years, 6 months.  The mean age of men was 60 years with a range of 41 
years, 11 months to 81 years, 6 months, and the mean age of women was 65 years with a 
range of 51 years, 1 month to 79 years, 8 months (See Table 2).  Most patients (82.8%) 
were fitted with a v.p. between 17 and 53 days following total laryngectomy.  The earliest 
v.p. fitting was performed 8 days after total laryngectomy, and the latest was at 263 days, 
with a mean period of 55 days and a median of 34 days.  
Prosthesis Lifetime 
Twenty-seven of the 29 patients who were available for long-term follow-up 
required TE prosthesis resizing.  The amount of change in v.p. length from the initial 
fitting to the end of the first year ranged from 0 to 12 mm.  Twenty-five patients required 
replacement prostheses which were shorter, 1 patient required replacement prostheses 
which were longer, and 2 patients’ prostheses remained the same in length from the 
initial fitting to the end of the first year.  The remaining patient had 4 therapy sessions in 
which the patient’s prosthesis remained the same in length from initial fitting until 
closure of the TEF and had 5 sessions in which the patient required a replacement 
prosthesis which was shorter from re-opening of the TEF to the end of the first year. 
Over the course of the first year, there was a strong tendency for refitting with a 
shorter v.p.  At initial fitting, the average v.p. length was 16.28 mm.  The range was 8 
mm to 28 mm, the mode was 18 mm, and the standard deviation was 4.68 mm.  At the 
end of the first year, the average v.p. length was 10.91 mm.  The range was 4.5 mm to 18 
mm, the mode was 10 mm, and the standard deviation was 3.2 mm (See Table 3). 
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Twenty-five of the 29 patients’ prostheses were 16 Fr. in diameter at the initial 
fitting, and only 4 of the 29 patients’ prostheses were 20 Fr. (InHealth) or 21 Fr. (Atos) at 
initial fitting.  However, 16 of the 29 patients were using a 16 Fr.v.p. at the end of the 
first year, and 13 of the 29 patients were using a 20 or 21 Fr.v.p. at the end of the first 
year.  At the initial post-operative session, more patients used 16 Fr.v.p.s than 20 French.  
This reflects the surgeon’s decision on tracheoesophageal puncture diameter and the 
initial use of the Provox 2 (21 Fr.) (See Table 4).   
Of the 29 patients available for long-term follow-up, three patients required at 
least one re-puncture, and TEP closure was evident in 2 patients just prior to 12 months.  
All three re-punctures occurred following patient report of difficulty in inserting the v.p. 
after cleaning.  One of these three patients switched from using a patient-inserted v.p. 
before re-puncture to using a clinician-inserted v.p. after re-puncture.  The remaining two 
patients with re-puncture continued to use a patient-inserted device after re-puncture.  
The patient who switched from a patient-inserted device to a clinician-inserted device and 
one of the patients who continued using a patient-inserted device were able to obtain at 
least functional TE speech.  Functional, in this case, refers to the ability to produce 
understandable sentence-length adult utterances.  However, the other patient who 
continued with a patient-inserted device was unable to obtain moderate TE speech until 
the very last session.  This patient was sidelined not only in TE speech but also in the use 
of an electrolarynx due to a pharyngocutaneous fistula, neck edema, and 
pharyngoesophageal spasm.  
Of the 2 patients with TEP closure just prior to the first year of recovery, only 1 
was able to obtain phrase length to conversational TE speech at some point in the first 
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year of recovery.  It is unknown why TEP closure occurred in this patient.  However, the 
other patient with TEP closure was hospitalized with recurrent cancer and could no 
longer care for the v.p.  This patient was unable to obtain phrase length to conversational 
speech in the first year of recovery because of radiation edema and PE spasm.  
A total of 104 v.p.s were removed and/or replaced in the 29 patients available for 
long-term follow-up.  Thirty-three of these v.p.s were removed and replaced, because the 
v.p. had worn out.  Of the 33 v.p.s that had worn out, 28 had been colonized with 
candida, and the valve broke in 5 v.p.s.  Seven of the 104 v.p.s were replaced by the 
speech-language pathologist (SLP), because the old v.p. had either been aspirated, lost, 
protruded into the airway inappropriately, or fell out.  It is unknown from the chart notes 
why 10 of the 104 v.p.s were removed and replaced by the SLP.  Manufacturer, type, 
length, and diameter remained the same from the previous therapy session, and the reason 
for v.p. replacement was not indicated in the chart.  Thirty-seven of the 104 v.p.s were 
removed and replaced with a shorter v.p.  Nineteen of the 37 v.p.s were not only replaced 
with a shorter v.p., but also were replaced with a different type of v.p.  Seven patient-
inserted devices were replaced with clinician-inserted devices, and the remaining 12 
patient-inserted devices were replaced with a different type of patient-inserted device.  
Eight of the 104 v.p.s were removed and replaced with a longer v.p.  Five of the 10 v.p.s 
were not only replaced with a longer v.p., but were also replaced with a different type of 
v.p.  Two ultra-low resistance v.p.s were replaced with low pressure v.p.s, 1 low pressure 
v.p. was replaced with an ultra-low resistance v.p., 1 low pressure v.p. was replaced with 
a duckbill v.p., and an Atos clinician-inserted v.p. was replaced with an Inhealth 
clinician-inserted v.p.  The remaining 9 of the 104 v.p.s were replaced because of the 
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decision either to use a different type of v.p. or a different manufacturer.  Four patient-
inserted v.p.s were replaced with a different type of patient-inserted v.p., 3 clinician-
inserted v.p.s were replaced with patient-inserted v.p.s, 1 patient-inserted v.p. was 
replaced with a clinician inserted v.p., and 1 Inhealth clinician-inserted v.p. was replaced 
with a Provox clinician-inserted v.p. 
Sixty-six of the 104 v.p.s that were removed (10 duckbill, 46 low pressure, & 10 
clinician-inserted) were Inhealth prostheses.  Thirty-three (22 ultra-low resistance & 11 
duckbill) were Bivona prostheses, and the remaining 5 prostheses were Atos’ Provox.  
The average lifetime of the clinician-inserted Atos Provox was 80.8 days, of the patient-
inserted Inhealth duckbill was 74.7 days, of the clinician-inserted Inhealth Indwelling 
was 74.7 days, of the patient-inserted Inhealth low pressure was 58.87 days, of the 
patient-inserted Bivona ultra-low resistance was 44.68 days, and of the patient-inserted 
Bivona-duckbill was 44.18 days. 
In summary, the sample contained 89 patient-inserted and 15 clinician-inserted 
v.p.s.  The average number of days between fittings of the clinician-inserted v.p.s was 
76.7 days.  The range was 14 to 220 days, the median was 62 days, and the standard 
deviation was 55.11 days.  The average number of days between fittings of the patient-
inserted v.p.s. was 55.33 days.  The range was 1 to 338 days, the median was 42 days, 
and the standard deviation was 54.6 days (See Table 5).  This indicates a relatively short 
useful life of the clinician-inserted v.p.s. 
At initial fitting, 27 of the 29 patients used a patient-inserted device, and only 2 
used a clinician-inserted device.  However, while most patients continued with patient-
inserted v.p.s there was a trend to increase the use of clinician-inserted devices in the first 
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year.  At the end of the first year, 22 patients used patient-inserted devices, and 7 used 
clinician-inserted devices (See Table 6). 
Twenty-eight (27%) of the 104 v.p.s were removed because of candida 
colonization, including 16 Inhealth prostheses (8 low pressure, 4 duckbill, & 4 clinician-
inserted), 8 Bivona prostheses (7 ultra-low resistance & 1 duckbill), and 4 Atos clinician-
inserted (Provox) prostheses.  Seven of 22 ultra-low resistance v.p.s (32%), 1 of 11 
Bivona duckbill v.p.s (9%), 4 of 10 Inhealth duckbill v.p.s (40%), 8 of 46 Inhealth low 
pressure v.p.s (17%), 4 of 10 Inhealth clinician-inserted v.p.s (40%), and 4 of 5 Atos 
clinician-inserted (Provox) v.p.s (80%) were colonized with Candida Albicans (See Table 
7). 
Complications  
 As mentioned previously, complications, in this instance, refer to anything that 
prevents, delays, or interferes with voice restoration via tracheoesophageal speech.  The 
complications of most concern in the present study were patient-related issues, such as an 
inability to readily occlude the stoma, pharyngoesophageal (PE) spasm, radiation-induced 
fibrosis, pneumonia, emphysema, recurrent cancer, and dysphagia, and prosthesis-related 
issues, such as candida colonization.   
Of the 29 patients available for long-term follow-up, 23 were able to obtain at 
least phrase length to conversational speech at some point in the first year of recovery.  
Of the remaining 6 patients who were not able to obtain phrase length to conversational 
speech in the first year of recovery, 2 had difficulty with stoma occlusion, TEP closure 
was evident in 1 just prior to the first year, 1 had extensive pharyngeal and esophageal 
reconstruction and dysphagia, and it is unknown why the remaining patient could not 
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produce conversational TE speech.  Of the 2 who had difficulty with stoma occlusion, 1 
also acquired neck edema, and the other acquired PE spasm and dysphagia.  The patient 
with TEP closure just prior to the first year of recovery was hospitalized with recurrent 
cancer and could no longer care for the v.p.  This patient was unable to obtain phrase 
length to conversational speech in the first year of recovery because of radiation edema 
and PE spasm.  
Of the 29 patients available for long-term follow-up, 7 had difficulty in stoma 
occlusion at some point in the first year of recovery, and PE spasm was evident in 8.  
Radiation-induced fibrosis, neck edema, mandibular and peristomal edema, post-
radiation erythema, and/or tissue devascularization was also evident in 8.  Of the 29 
patients, 1 had pneumonia, 3 developed recurrent cancer, 5 had some form of dysphagia, 
and 13 patients had candida colonization on their v.p. at some point in the first year of 
recovery.       
    Discussion 
 The present study was performed to gain a better understanding of how v.p. 
length changes in the first year of recovery, how v.p. diameter changes in the first year of 
recovery, how many patients switch from a patient-inserted v.p. to a clinician-inserted 
v.p. and vice versa in the first year of recovery, whether there are gender-related 
differences in speech rehabilitation in the first year of recovery, whether clinician-
inserted v.p.s really last longer than patient-inserted v.p.s, how long these v.p.s last before 
they wear out, and whether there are factors in patient speech rehabilitation more 
commonly found following radiation.  
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How does prosthesis length change in the first year of recovery?  The primary 
trend in the present study identified a reduction in v.p. length over the first year.  At the 
end of the first year, 25 of the 29 patients available for long-term follow-up required 
replacement v.p.s which were shorter than at initial fitting.  At initial fitting, the average 
v.p. length was 16.28 mm.  The range was 8 mm to 28 mm, the mode was 18 mm, and 
the standard deviation was 4.68 mm.  At the end of the first year, the average v.p. length 
was 10.91 mm.  The range was 4.5 mm to 18 mm, the mode was 10 mm, and the standard 
deviation was 3.2 mm (See Table 3).   
How does prosthesis diameter change in the first year of recovery?  Twenty-
five of the 29 patients’ prostheses were 16 Fr. in diameter at the initial fitting, and only 4 
were 20 Fr. (InHealth) or 21 Fr. (Atos) at initial fitting.  However, 16 of the 29 patients 
were using a 16 Fr.v.p. at the end of the first year, and 13 were using a 20 or 21 Fr.v.p. at 
the end of the first year.  At the initial post-operative session, more patients used 16 Fr. 
v.p.s than 20 or 21 French.  This reflects the surgeon’s decision on tracheoesophageal 
puncture diameter and the initial use of the Provox 2 (21 Fr.) (See Table 4).  
How many patients switch from a clinician-inserted v.p. to a patient-inserted 
v.p. and vice versa in the first year of recovery?  At initial fitting, 27 of the 29 patients 
used a patient-inserted device, and only 2 of the 29 patients used a clinician-inserted 
device.  However, while most patients continued with patient-inserted v.p.s there was a 
trend to increase the use of clinician-inserted devices in the first year.  At the end of the 
first year, 22 patients used patient-inserted devices, and 7 used clinician-inserted devices 
(See Table 6). 
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Are there gender-related differences in speech rehabilitation in the first year 
of recovery?  A reduction in length of the v.p. over the first year was evident in both 
males and females.  The average length of v.p. at initial fitting and at the end of the first 
year for women was 15.11 mm and 10 mm, respectively (see Table 8).  Whereas, the 
average length of v.p. at initial fitting and at the end of the first year for men was 16.6 
mm and 11.33 mm, respectively (see Table 9).     
 The number of speech therapy sessions did not differ as a function of patient 
gender either.  There were 9 females consisting of 76 total visits and 20 males consisting 
of 135 total visits.  This amounts to approximately 8.4 visits per female and 6.75 visits 
per male.  The patient is scheduled to see the surgeon every 6 to 8 weeks, and because 
many patients must travel a long distance to get to the clinic, the speech-language 
pathologist tries to schedule voice therapy sessions on the same day.  This suggests that 
the patients were seen on a regular schedule.   
Neither length nor speech therapy sessions differed as a function of patient 
gender.  However, there was a difference in age among gender at the time of surgery.  
Females tended to be older than males at the time of surgery.  The mean age of females 
and males at the time of surgery was 65 years and 60 years, respectively.  The age of 
females ranged from 51 years: 1 month to 79 years: 8 months at the time of surgery, 
whereas the age of males ranged from 41 years: 11 months to 81 years: 6 months at the 
time of surgery (see table 2).  
Do clinician-inserted v.p.s really last longer than patient-inserted v.p.s?  As 
mentioned previously, the clinician-inserted v.p. is a more recent development that was 
created in hopes of solving self-care issues.  They contain larger tracheal and esophageal 
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retention collars requiring a significantly greater effort to remove and replace the v.p. 
(Stemple, Glaze, & Klaben, 2000).  Although these v.p.s are reputed to be more durable 
(lasting approximately 6 to 12 months), they are also more expensive (InHealth 
Technologies Price List, 2005) and the present data do not support the claim of increased 
durability, at least not durability commensurate with cost.  Therefore, it would be 
beneficial to the patient, if the patient was aware of whether the clinician-inserted v.p. 
really lasts longer than the patient-inserted device.   
Unfortunately, the clinician-inserted v.p. proved to have a relatively short useful 
life in the present study.  The sample contained 89 patient-inserted and 15 clinician-
inserted v.p.s.  The average number of days between fittings of the clinician-inserted v.p.s 
was 76.7 days.  The range was 14 to 220 days, the median was 62 days, and the standard 
deviation was 55.11 days.  The average number of days between fittings of the patient-
inserted v.p.s. was 55.33 days.  The range was 1 to 338 days, the median was 42 days, 
and the standard deviation was 54.6 days (See Table 5).   
However, durability is not the only issue in selecting a clinician-inserted device.  
A clinician-inserted device may also be selected in regards to self-care issues.  The 
patient may not be able to remove, clean, and reinsert the device themselves for various 
reasons, including poor eye sight, poor fine motor skills, and hospitalization of the patient 
due to pneumonia or recurrent cancer, and etcetera.  
There are also reasons for not selecting a clinician-inserted device.  One reason is 
expense.  As mentioned previously, clinician-inserted v.p.s are purported to last longer, 
thus they are more expensive.  As of March 1, 2005, Inhealth’s patient-inserted duckbill 
v.p. was only 27 dollars, and the low pressure v.p. was only 43 dollars.  However, 
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Inhealth’s clinician-inserted v.p. was 125 dollars (Inhealth Technologies Patient Price 
List, 2005), and as of February 1, 2005, Atos’s clinician-inserted v.p. was 199 dollars 
(Atos Medical price list, 2005).  As of 7/1/05, Medicare’s reimbursement for all voice 
prostheses, regardless of actual cost, was $88.09.  Aetna’s reimbursement was $78.69, 
United Health Care’s reimbursement was $136.00, and Medical Mutual’s reimbursement 
was $74.00 (Billing Information on Patient Records).  The cost exceeds the rate of 
reimbursement for clinician-inserted v.p.s. 
How long do these v.p.s last before they wear out?  A total of 104 v.p.s were 
removed and/or replaced in the 29 patients available for long-term follow-up.  Thirty-
three of these v.p.s were removed and replaced, because the v.p. had worn out.  Of the 33 
v.p.s that had worn out, 28 (27%) had been colonized with candida, and the valve broke 
in 5 v.p.s.  The 33 v.p.s lasted an average of 76 days from fitting of the v.p. to removal do 
to candida colonization or a worn out valve.  The range was 2 to 338 days, the median 
was 54 days, and the standard deviation was 71.  There were 11 Bivona ultra-low 
resistance v.p.s, 9 Inhealth low pressure v.p.s, 4 Inhealth Indwelling v.p.s, 4 Inhealth 
duckbill v.p.s, 4 Atos Provox II v.p.s, and 1 Bivona duckbill v.p. that were colonized with 
candida.  Of the 5 v.p.s with broken valves, 4 were ultra-low resistance v.p.s, and 1 was a 
low pressure v.p.    
Are there factors in patient speech rehabilitation more commonly found 
following radiation?  Another trend was the pervasive presence of candida colonization 
of voice prostheses.  Past studies have recognized that it is common for patients who have 
had radiation treatment to colonize candida albicans on their v.p.s.  In the present study, 
22 of the 29 patients available for long-term follow-up also underwent radiation therapy 
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either before or after surgery.  More specifically, 17 of the 22 patients underwent 
radiation therapy post-operatively, and 5 underwent radiation therapy pre-operatively.  Of 
these 22, 10 exhibited candida on their v.p.s.  However, 12 other patients who underwent 
radiation therapy either before or after surgery did not.  Of the 10 patients who exhibited 
candida on their v.p.s, 8 had received radiation treatment post-operatively, and the 
remaining 2 had received radiation pre-operatively.  Of the 12 patients who underwent 
radiation therapy either before or after surgery and did not exhibit candida, 9 had 
received radiation treatment post-operatively, and 3 had received radiation pre-
operatively.  Essentially 55% of the patients with radiation therapy did not colonize their 
v.p.s.  Furthermore, of the 7 patients who did not receive radiation therapy, 3 exhibited 
candida colonization, and 4 did not (See Table 10). 
 Since radiation therapy is typically limited to the first year of recovery, but 
occupies a significant amount of time in that year (6 weeks of treatment and 3-6 months 
of recovery) this is an important factor in the first year’s progress for these patients, but 
should not be such a factor in subsequent years.  Hence, there is a need for continued 
study of recovery, at least into the second year.  This marks the first of two limitations of 
the present study. 
The second limitation deals with the fact that there are advanced prostheses that 
were not available during this study, including the Blom-Singer Indwelling Advantage & 
the Provox ActiValve.  The Blom-Singer Indwelling Advantage is a clinician-inserted 
device that contains silver oxide in the silicone flap valve in order to prevent candida 
colonization.  This device also includes an easy-fold esophageal retention flange and 
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flange introducer, a brush and flush cleaning system with built-in safety features, and 
taper-tip gel cap insertion (Inhealth Product Catalog, 2005). 
The Provox ActiValve was designed to prevent excessive candida growth and to 
help prevent inadvertent opening.  Candida is prevented due to a valve seat made of a 
candida resistant material, and inadvertent opening is prevented by means of magnets 
holding the valve and valve seat together (Atos Medical Catalog, 2005).  Future studies 
may want to address these newer types of v.p.s. 
    Conclusion 
Today, speech-language pathologists and otolaryngologists face a myriad of 
decisions when assisting the laryngectomee.  These decisions greatly affect the 
restoration of voice and can prevent isolation and depression for the post-laryngectomy 
patient.  Three trends that are beneficial in the clinical decision-making process were 
identified in the present study.  These are a reduction in v.p. length over the first year, a 
relatively short useful life of the clinician-inserted v.p.s, and a pervasive presence of 
candida colonization of v.p.s.  All three trends involve factors considered in the decision 
making process, including durability, expense and patient ability to care for the v.p.   
The primary trend in the present study was a reduction in v.p. length over the first 
year of recovery.  If voice prosthesis length dramatically decreases throughout the first 
year, durability should not be an issue.  It would not be wise to buy a more durable device 
that is purported to last approximately 6 to 12 months and is more expensive, if a shorter 
v.p. is needed before this time frame has expired or before the more durable prosthesis 
has worn out.  The data indicate that patients in the first year of recovery require new 
v.p.s not only because of eventual weakening of the valve, but more commonly because 
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there is a need for a shorter v.p.  This raises two clinical issues: first, patients need to be 
seen frequently in the first year to monitor voice prosthesis length, and second, durability 
of the valve does not appear to offer significant value in the first year of recovery.  Since 
there is likely to be frequent v.p. changes in the this time frame, selection of the less 
expensive pt. inserted devices would serve to reduce overall costs.  As mentioned 
previously, the clinician-inserted v.p. is more expensive, and this cost exceeds the rate of 
reimbursement.   
However, durability and expense are not the only issues in selecting or not 
selecting a clinician-inserted device.  Clinician-inserted devices were also created in 
hopes of solving self-care issues.  The patient may not be able to remove, clean, and 
reinsert the device themselves for various reasons, including poor eye sight, poor fine 
motor skills, and hospitalization of the patient due to pneumonia or recurrent cancer, etc.  
Cost, therefore, is only one factor the clinician should consider in deciding between a pt. 
inserted or a clinician inserted device.   
The second trend in the present study was the relatively short useful life of the 
clinician-inserted v.p.s.  As mentioned previously, a total of 104 v.p.s were removed 
and/or replaced in the 29 patients available for long-term follow-up.  Of the 104 v.p.s, 
there were 15 clinician-inserted devices and 89 patient-inserted devices.  The average 
number of days between fittings of the clinician-inserted v.p.s was 76.7 days, and the 
median was 62 days.  The average number of days between fittings of the patient-inserted 
v.p.s. was 55.33 days, and the median was 42 days (See Table 5).  On average the 
clinician-inserted v.p.s were only in place 21.37 days longer than the patient-inserted 
v.p.s.  These v.p.s were replaced for various reasons including the presence of candida 
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(28), a worn out valve (5), the need for a shorter v.p. (37), the need for a longer v.p. (8), 
an aspirated, lost, or protruded v.p. (7), the decision to use a different type or 
manufacturer (9), or unknown reasons (10).     
The third trend in the present study was a pervasive presence of candida 
colonization of v.p.s.  Past studies have recognized that it is common for patients who 
have had radiation treatment to colonize candida albicans on their v.p.s.  In the present 
study, 22 of the 29 patients available for long-term follow-up underwent radiation 
therapy either before or after surgery.  However, candida was not present after radiation 
in just as many patients who did develop candida after radiation.  More specifically, 10 
developed candida after radiation, and 12 did not develop candida after radiation.  
Essentially, 54.5% of the patients with radiation therapy did not colonize their v.p.s.  
These data run counter to the expectation of some that candida colonization tends to be a 
complication of radiation therapy (See Table 10). 
Eight of the 15 clinician-inserted devices (53.3%) and 25 of the 89 patient-
inserted devices (28%) were removed and replaced either because the valve broke (Low 
Pressure or Ultra Low Resistance) or the valve was leaking, typically associated w/ 
candida colonization.  Clinician-inserted devices may increase ease of patient care and 
the valve appeared more robust to damage; however, their useful life in the first year was 
shorter than anticipated.  The present data demonstrated the pervasiveness of candida 
among these patients.  Given the cost of the clinician-inserted devices and the ubiquity of 
candida colonization (27% overall), clinicians should give serious consideration to use of 
antifungal medications early in these patients’ recovery, rather than waiting for premature 
valve breakdown. 
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Clinicians have had the option of tracheoesophageal puncture for voice restoration 
for a quarter century.  While the concept is simple (coupling the pulmonary airstream to 
the esophagus for phonation), the application has and continues to evolve.  Changes in 
cancer treatment, changes in technology which permits new design of valves, and patient-
specific factors challenge clinicians in the successful management of patient speech 
rehabilitation.   An important source of knowledge for clinical decision-making is the 
progress of the patient themselves.  The present study reviewed the first year of recovery 
and found that the one constant was change.  Clinicians should prepare their patients for 
this change and to base their treatment plans on the need to monitor for and control this 
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Table 1. Voice Prostheses in the Present Study 
 
 




8 lengths -  
1.4cm to 3.3cm 







7 lengths – 
1.4cm to 3.0cm 






9 lengths – 
6mm to 28mm 
16 Fr. $27.00 as of 




9 lengths – 
6mm to 28mm 
16 Fr. & 20 Fr. $43.00 as of 




8 lengths – 
6mm to 25mm 
16 Fr. & 20 Fr. $125.00 as of 




5 lengths – 
4.5mm to 
12.5mm 
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Males (20) 60 Years 41:11 to 81:6 
Females (9) 65 Years 51:1 to 79:8  
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16.28 mm 8 mm to 28 
mm  
18 mm 4.68 mm 
12 Months 10.91 mm 4.5 mm to 18 
mm 
10 mm 3.2 mm 
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  16 French 20 (21) French 
Initial Fitting 25 4 
End of First Year 16 13 
*At the initial post-operative session, more pts. used 16 Fr. v.p.s than 20 Fr.  This reflects 
the surgeons’ decision on tracheoesophageal puncture diameter and the initial use of the 
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15 76.7 days 14 to 220 
days 
62 days 55.11 days 
Patient-inserted 89 55.33 days 1 to 338 
days 
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  Initial Fitting First Year 
Clinician-Inserted 2 7 
Patient-Inserted 27 22 
While most pts. continued with Patient-Inserted v.p.s there was a trend to increase the use 
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4 of 10 (40%) 121.25 21 to 338 147.387 
Inhealth Low 
Pressure 





4 of 10 (40%) 84 14 to 220 92.76 
Bivona 
Duckbill 
1 of 11 (9%)   21   
Bivona Ultra- 
Low Resistance 
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  Average 
Length 




15.11 mm 8 to  
22 mm 
18mm 4.26 mm 
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  Average 
Length 




16.6 mm 8 to  
28 mm 
18 mm 4.73 mm 
12 Months 11.33 mm 4.5 to  
18 mm 
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  Candida No Candida 
Radiation 10 12 
No Radiation 3 4 
*These data run counter to the expectation of some that candida colonization tends to be 
a complication of radiation therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
